neuraxon


Also found in: Dictionary.

neu·rax·on

, neuraxone (nū-rak'son, -sōn),
Obsolete term for axon.
[neur- + G. axōn, axis]

neuraxon

, neuraxone (nū-răks′ōn)
A term formerly used for an axon.

neuraxon

axon.
References in periodicals archive ?
At Ventures West, he currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics, NeurAxon and Presidio Pharmaceuticals.
NeurAxon, a Canadian company, has developed a first-in-class selective inhibitor of the neuronal form of NOS, which modulates the central and peripheral response to pain and neuronal sensitization.
Bloch served as chief executive officer of NeurAxon, Inc.
2 Interview with Dr John Andrews, President and Chief Scientific Officer, NeurAxon.
Companies covered include: Abbott, AcelRx, Acura, Afferent, Algiax, Arcion, Astellas, BioDelivery Sciences, Cara, Cephalon, Convergence, Cytogel, DURECT, Egalet, Eli Lilly, Endo, Grunenthal, Hospira, iMed, Johnson & Johnson, KemPharm, Mallinckrodt, NeurAxon, NeurogesX, Newron, Novartis, Nuvo, Pacira, Pain Therapeutics, Pfizer, Purdue, QRx, Relevare, Relmada, Spinifex, Xenon, Xenoport, Zalicus and Zogenix.
Agreement Covers Screening Services to NeurAxon Inc.
Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including NXN-188, an oral, first-in-class selective nNOS inhibitor and 5HT agonist and NXN-462, an oral selective nNOS inhibitor.
Andy is currently also Chairman and CEO of Kymab and is a non-executive director of NeurAxon and PBL.
The NeurAxon presentation will be delivered on Tuesday, November 16, 2010 at 2:10 pm Eastern Time at the St.
NeuraLieve Neuralynx Neuraxon Neurion Pharmaceuticals Neuro3d Neurobiological Technologies Neurochem NeuroControl Neurocrine NeuroCure Neurodan Neurogen Corp.
In this study we evaluated Total Migraine Freedom, the complete absence of all pain, nausea, and sensitivity to light and sound, and found that a significant proportion of patients receiving NXN-188 reported that all of their migraine symptoms had abated," said NeurAxon Chief Medical Officer, Robert Medve, M.
a worldwide leader in providing innovative and reliable solutions to experimental scientists, today announced a licensing agreement for its BioMedCAChe(TM) suite of automated docking and molecular modeling software with NeurAxon, Inc.